2Nafissi S,Vahabi Z,Sadeghi Ghahar M,et al.The role of cytomegalovirus,Haemophilus influenzae and Epstein Barr virus in Guillain Barre syndrome[J] .Acta Med Iran,2013,51(6):372-376.
3McLauchlan DJ,Robertson NP.Epidemiological aspects of Guillain-Barre syndrome[J] .J Neurol,2013,260(7):1942-1945.
4van den Berg B,Bunschoten C,van Doorn PA,et al.Mortality in Guillain-Barre syndrome[J] .Neurology,2013,80(18):1650-1654.
5Prevots DR,Sutter RW.Assessment of Guillain-Barré syndrome mortality and morbidity in the United States:implications for acute flaccid paralysis surveillance[J] .J Infect Dis,1997,175 Suppl 1:S151-S155.
6Cheng Q,Wang DS,Jiang GX,et al.Prospective study of clinical epidemiology of Guillain-Barré syndrome in Harbin,China[J] .J Neurol Sci,2003,215(1/2):63-69.
7吴江,贾建平,崔丽英,等.神经病学[M] .2版北京:人民卫生出版社,2011:130-132.
8Lehmann HC,Hartung HP.Plasma exchange and intravenous immunoglobulins:mechanism of action in immune-mediated neuropathies[J] .J Neuroimmunol,2011,231(1/2):61-69.
9Shahrizaila N,Yuki N.The role of immunotherapy in Guillain-Barre syndrome:understanding the mechanism of action[J] .Expert Opin Pharmacother,2011,12(10):1551-1560.
10Stangel M,Compston A,Scolding NJ.Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins("IVIg")[J] .J Neuroimmunol,2000,103(2):195-201.
